FDA Approval Summary: Dabrafenib in Combination with Trametinib for <i>BRAF</i>V600E Mutation–Positive Low-Grade GliomaMichael I. Barbato, Nicole Drezner, Sachia G. Khasar et al.|Clinical Cancer Research|2023Cited by 70
FDA Approval Summary: Repotrectinib for Locally Advanced or Metastatic ROS1-Positive Non–Small Cell Lung CancerMichael I. Barbato, Nicole Drezner, Diana Bradford et al.|Clinical Cancer Research|2024Cited by 13